CAR-T cell therapy shows early promise for HIV control

A small study has found that CAR-T cell therapy may offer a new way to manage HIV over the long term. The approach, already used to treat certain cancers, involves engineering a patient’s own immune cells.

Researchers are repurposing the treatment for HIV after seeing positive early signs in two individuals. The modified cells appear to help control the virus without the need for constant intervention.

相关文章

Illustration of a German woman achieving complete remission from three autoimmune diseases via groundbreaking CAR-T therapy, symbolizing hope and medical triumph.
AI 生成的图像

CAR-T therapy achieves complete remission of three autoimmune diseases in German woman

由 AI 报道 AI 生成的图像

A 47-year-old woman bedridden with autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome has achieved complete remission after CAR-T cell therapy at University Hospital Erlangen in Germany. Treated by Fabian Müller after nine failed therapies, she recovered rapidly and remains healthy over a year later without medication—the first simultaneous treatment of multiple autoimmune diseases with this method.

A study published on Monday in Nature Microbiology confirms long-term HIV remission in the «Oslo patient», a 62-year-old man treated for myelodysplasia via stem cell transplant from his brother carrying the CCR5 Delta 32 mutation. He has been off antiretrovirals for four years with no detectable virus. This brings the total to ten patients deemed cured this way.

由 AI 报道

Researchers have found that making cancer cells stiffer can enhance the effectiveness of car t-cell therapy against aggressive tumors. In experiments with mice, the approach led to complete tumor disappearance in some cases. The findings were presented recently at a conference in London.

An experimental therapy using stem cells from young donors has shown promise in improving mobility for frail older people. In a trial involving 148 participants, infusions of laromestrocel led to significant gains in walking distance. Researchers highlight its potential to address biological roots of frailty.

由 AI 报道

厚生劳动省专家小组有条件批准了两款用于治疗帕金森病和严重心脏病的诱导多能干(iPS)细胞衍生再生医学产品。这标志着诺贝尔奖获奖干细胞技术商业化的潜在世界首例。该批准基于小规模临床试验确认的安全性和假定疗效,要求在七年内在上市后进行验证。

此网站使用 cookie

我们使用 cookie 进行分析以改进我们的网站。阅读我们的 隐私政策 以获取更多信息。
拒绝